Beam Therapeutics Inc (NASDAQ: BEAM) is a clinical-stage genetic medicines company that develops base editing therapies designed to make precise changes to DNA and RNA. The company does not generate product revenue from approved medicines. It funds operations primarily through collaboration agreements, upfront payments, and milestone payments from partners, as disclosed in its 10-K filed 2026-02-24 (accession 0001193125-26-065194). Beam is a pre-commercial biotechnology company operating entirely at the research and clinical development stage. No approved products, segment revenue breakdown, customer counts, or competitor names are identified in the available filing excerpts, and no such details are included here.

Revenue model

Collaboration agreements, upfront payments, and milestone payments from partners. No approved product revenue as of the 10-K filed 2026-02-24.

Products and services

Base editing genetic medicines in clinical and preclinical development. No approved products identified in the available filing excerpts.

Value-chain role

Drug developer, clinical-stage. No commercial manufacturing or distribution role identified in the available filing excerpts.

Source: SEC 10-K, filed 2026-02-24

Industry: Biological Products, (No Diagnostic Substances) Peers: AMICUS THERAPEUTICS, INC. Arrowhead Pharmaceuticals Inc Blueprint Medicines Corp ChemoCentryx, Inc. Denali Therapeutics Inc Mirati Therapeutics, Inc. PTC Therapeutics Inc Ultragenyx Pharmaceutical Inc